Gilead’s Bulevirtide Demonstrates Long-Term Sustained Virologic Response For Hepatitis D
At the ongoing European Association for the Study of the Liver (EASL) Congress 2025, Gilead announced findings on its hepatitis D (HDV) therapy, bulevirtide. Specifically, the therapy was studied as a standalone treatment and in combination with pegylated interferon alpha (PegIFN). In patients with compensated chronic hepatitis D (CHD), achieving undetectable HDV RNA with “target […]
Lyme Prevention and Next-Gen Diagnostics
Multiplex protein microarray Image credits: Jason Barker, ND As tick season takes hold across the country, healthcare professionals are emphasizing prevention and early detection of tick-borne illnesses, particularly Lyme disease. In recognition of Lyme Disease Awareness Month, Vibrant Wellness clinical lab educator Jason Barker, ND, shared practical prevention strategies and diagnostic updates in a recent […]
Researchers map 7,000-year-old genetic mutation that protects against HIV
Modern HIV medicine is based on a common genetic mutation. Now, researchers have traced where and when the mutation arose — and how it protected our ancestors from ancient diseases. What do a millennia-old human from the Black Sea region and modern HIV medicine have in common? Quite a lot, it turns out, according to […]
Novel, needle-free, live-attenuated influenza vaccines with broad protection against human and avian virus subtypes
A research team led by the School of Public Health in the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with the Centre for Immunology & Infection (C2i), has achieved a significant breakthrough in developing broadly protective, live-attenuated influenza vaccines (LAIV). These innovative LAIV platforms offer potential to develop universal influenza […]
US Businesses Are Here to Help the Trump Administration Keep its Pledge to End HIV
Stephen MasseyImage credit: Meteorite In 2019, President Donald J. Trump set a historic goal: end the HIV epidemic in the United States by 2030. It was a bold vision that rallied unprecedented support across sectors, including from leaders in the business community who’ve stepped up to help achieve that goal. Over the past several years, […]
RSV Prophylaxis: Palivizumab, Nirsevimab, and More
RSV prophylaxis: Palivizumab, nirsevimab, and more | Image Credit: © John Doe – © John Doe – stock.adobe.com. This post was originally published on our sister site, ContemporaryPediatrics, as a part of their May 2025 journal. Respiratory syncytial virus (RSV) illness is an extremely common cause of hospitalization in children in the United States and […]
Early Release – Beyond the Brushstrokes—Illuminating Patterns and Interactions to Find Order in Complex Systems – Volume 31, Supplement—May 2025 – Emerging Infectious Diseases journal
Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D. MacCannell, S. Santibanez); The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA (B. MacInnis) […]
One Million New Pediatric HIV Cases Predicted If PEPFAR Funding Is Cut
For the past 2 decades, the US President’s Emergency Plan for AIDS Relief (PEPFAR) has provided more than $110 billion toward the global HIV/AIDS response. If this funding stops—as suggested by a recent directive—infections and deaths are expected to rise significantly, including 1 million new pediatric cases of HIV and 460 000 additional AIDS-related deaths in […]
